Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Health Research Projects

Université de Montréal

$107,678.00

Testing of a sclerosing and embolizing gel for venous disease

EF 2022-23

Résumé
Varicose veins are a part of a spectrum of manifestations of chronic vein disorders that arecharacterized by the occurence of blood reflux in incompetent veins leading to vein dilatation.Varicose veins are often observed in lower legs due valve failure of the great saphenous vein(GSV). Beside aesthetic concern, edema and pain, varicosities can lead to seriouscomplications such as leg ulcers. The recent estimates of the prevalence of varicosities in theUnited States range from 15% among men to 28% in women. Varicose veins are alsoobserved in gonadal veins causing severe abdominal pain in women and testicular pain andinfertility in men. Gastro-esophageal varices veins are often observed in cirrhosis patient withportal hypertension leading to life threatening bleeding.Different techniques were proposed to treat varicose veins. Mechanical techniques such asligation, stripping, occlusion with mechanical devices are used to prevent reflux whereaschemical ablation with sclerosant or thermal ablation with laser or radiofrequency probes aimto destroy the wall of the vein. These therapies are often used in combination and the resultscan be suboptimal leading to recurrence of symptoms and redo procedures leading toincrease cost and deterioration of the quality of life.We have developed and patented a sclerosing and embolizing gel at CRCHUM made ofchitosan a bio-absorbable gel combined with a sclerosant agent (Sodium Tetradecyl Sulfate).This gel is also visible under X-ray and ultrasound which allows safe delivery under imagingguidance.The gel was licensed to Cook Medical (USA), a world leader company in the development ofmedical device for interventional radiology. We propose in partnership with Cook Medical andChitolytic, a canadian company supplying pharmaceutical grade chitosan, to develop aformulation specifically adapted for venous sclerotherapy and test it in a porcine venousmodel.
Programme
Collaborative Health Research Projects
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
549711-2020
Name nom
Soulez, Gilles G
Department département
Radiologie, radio-oncologie et médecine nucléaire
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2022
Competition year année de concours
2020
Award amount
107678
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9000
Research subject group en
Medical sciences
Research subject group fr
Sciences médicales
Research subject en
Medical sciences
Research subject fr
Sciences médicales
Installment
inst:4
Partie
1
Nb partie
4
Application title
Testing of a sclerosing and embolizing gel for venous disease
Application summary
Varicose veins are a part of a spectrum of manifestations of chronic vein disorders that arecharacterized by the occurence of blood reflux in incompetent veins leading to vein dilatation.Varicose veins are often observed in lower legs due valve failure of the great saphenous vein(GSV). Beside aesthetic concern, edema and pain, varicosities can lead to seriouscomplications such as leg ulcers. The recent estimates of the prevalence of varicosities in theUnited States range from 15% among men to 28% in women. Varicose veins are alsoobserved in gonadal veins causing severe abdominal pain in women and testicular pain andinfertility in men. Gastro-esophageal varices veins are often observed in cirrhosis patient withportal hypertension leading to life threatening bleeding.Different techniques were proposed to treat varicose veins. Mechanical techniques such asligation, stripping, occlusion with mechanical devices are used to prevent reflux whereaschemical ablation with sclerosant or thermal ablation with laser or radiofrequency probes aimto destroy the wall of the vein. These therapies are often used in combination and the resultscan be suboptimal leading to recurrence of symptoms and redo procedures leading toincrease cost and deterioration of the quality of life.We have developed and patented a sclerosing and embolizing gel at CRCHUM made ofchitosan a bio-absorbable gel combined with a sclerosant agent (Sodium Tetradecyl Sulfate).This gel is also visible under X-ray and ultrasound which allows safe delivery under imagingguidance.The gel was licensed to Cook Medical (USA), a world leader company in the development ofmedical device for interventional radiology. We propose in partnership with Cook Medical andChitolytic, a canadian company supplying pharmaceutical grade chitosan, to develop aformulation specifically adapted for venous sclerotherapy and test it in a porcine venousmodel.